Passively acquired antibody directed at human erythrocytes seen during therapy with Minnesota antilymphoblast globulin.
6 renal transplant patients, seen at the Mayo Clinic between July 1982 and April 1983, received Minnesota antilymphoblast globulin (MALG) for treatment of allograft rejection and demonstrated warm-acting 'auto'-antibodies during such therapy. These antibodies represented xenogeneic reactivity in equine MALG, rather than the products of patient-derived immune responses, since they were not detected before or after the period of therapy with this immunosuppressive agent in any of the 6 cases. They interfered with crossmatch procedures for red cell transfusion, and were only variably removed by autoabsorption techniques. Heat treatment of sera containing MALG-related red cell antibodies was ineffective in abrogating their reactivity and also compromised the reactivity of some red cell alloantibodies which were tested as controls. Transfusion of 'least-incompatible' red blood cells had no adverse effects in 2 cases where it was necessitated by clinical circumstances, despite an inability to obtain suitable serological samples for crossmatching.
D000328:Adult; D000961:Antilymphocyte Serum / Q000009:adverse effects / Q000627:therapeutic use*; D001323:Autoantibodies / Q000096:biosynthesis*; D001803:Blood Transfusion; D004912:Erythrocytes / Q000276:immunology*; D005260:Female; D006084:Graft Rejection; D006801:Humans; D007116:Immunization, Passive; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged
D000961:Antilymphocyte Serum; D001323:Autoantibodies